Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies

References

• Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973.e33.
   PubMed Web of Science ®Google Scholar
• Baldwin H, Webster G, Stein Gold L, et al. 50 Years of topical retinoids for acne: evolution of treatment. Am J Clin Dermatol. 2021;22(3):315–327.
   PubMed Web of Science ®Google Scholar
• Kolli SS, Pecone D, Pona A, et al. Topical retinoids in acne vulgaris: a systematic review. Am J Clin Dermatol. 2019;20(3):345–365.
   PubMed Web of Science ®Google Scholar
• Sevimli Dikicier B. Topical treatment of acne vulgaris: efficiency, side effects, and adherence rate. J Int Med Res. 2019;47(7):2987–2992.
   PubMed Web of Science ®Google Scholar
• Thiboutot DD, Rosso JQ. Acne vulgaris and the epidermal barrier. J Clin Aesthet Dermatol. 2013;6(2):18–24.
   PubMedGoogle Scholar
• Tolaymat L, Dearborn H, Zito PM. Adapalene. Treasure Island (FL). StatPearls Publishing; 2022.
   Google Scholar
• Culp L, Moradi Tuchayi S, Alinia H, et al. Tolerability of topical retinoids: are there clinically meaningful differences among topical retinoids? J Cutan Med Surg. 2015;19(6):530–538.
   PubMed Web of Science ®Google Scholar
• Leyden J, Grove G, Zerweck C. Facial tolerability of topical retinoid therapy. J Drugs Dermatol. 2004;3(6):641–651.
   PubMedGoogle Scholar
• Shroot B. Pharmacodynamics and pharmacokinetics of topical adapalene. J Am Acad Dermatol. 1998;39(2 Pt 3):S17–S24.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Ioannides D, Kalogeromitros D, et al. Comparison of topical retinoids in the treatment of acne. Clin Dermatol. 2004;22(5):408–411.
   PubMed Web of Science ®Google Scholar
• Differin® (adapalene) gel 0.3%. US prescribing information. Fort Worth, TX: Galderma; 2012.
   Google Scholar
• Arazlo® (tazarotene) lotion 0.045%. US prescribing information. Bridgewater, NJ: Ortho Dermatologics; 2021.
   Google Scholar
• Tanghetti EA, Stein Gold L, Rosso, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat. 2021;32(4):391–398.
   PubMed Web of Science ®Google Scholar
• Cosio T, Di Prete M, Gaziano R, et al. Trifarotene: a current review and perspectives in dermatology. Biomedicines. 2021;9(3):237.
   PubMed Web of Science ®Google Scholar
• Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691–1699.
   PubMed Web of Science ®Google Scholar
• Aklief® (trifarotene) 0.005% cream. US prescribing information. Fort Worth, TX: Galderma; 2019.
   Google Scholar
• Draelos ZD, Tanghetti EA, Guenin E. Vehicle formulation impacts tolerability and patient preference: comparison of tretinoin branded lotion and generic cream. J Drugs Dermatol. 2022;21(8):875–880.
   PubMed Web of Science ®Google Scholar
• Berger RS, Bowman JP. A reappraisal of the 21-day cumulative irritation test in man. J Toxicol: Cutan Ocular Toxicol. 1982;1(2):109–115.
   Google Scholar
• Kircik LH, Green L, Guenin E, et al. Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials. J Dermatolog Treat. 2022;33(4):2241–2249.
   PubMed Web of Science ®Google Scholar
• Eicher L, Knop M, Aszodi N, et al. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease - strategies for optimizing treatment outcome. J Eur Acad Dermatol Venereol. 2019;33(12):2253–2263.
   PubMed Web of Science ®Google Scholar
• Hoffman LK, Bhatia N, Zeichner J, et al. Topical vehicle formulations in the treatment of acne. J Drugs Dermatol. 2018;17(6):s6–s10.
   PubMedGoogle Scholar
• Stuart B, Maund E, Wilcox C, et al. Topical preparations for the treatment of mild-to-moderate acne vulgaris: systematic review and network meta-analysis. Br J Dermatol. 2021;185(3):512–525.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Castelli M, Komaroff M, et al. Pharmacokinetic profile of the asenapine transdermal system (HP-3070). J Clin Psychopharmacol. 2021;41(3):286–294.
   PubMed Web of Science ®Google Scholar
• Galvin SA, Gilbert R, Baker M, et al. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations. Br J Dermatol. 1998;139 Suppl 52:34–40.
   PubMed Web of Science ®Google Scholar
• Brand B, Gilbert R, Baker MD, et al. Cumulative irritancy comparison of adapalene gel 0.1% versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol. 2003;49(3 Suppl):S227–S32.
   PubMed Web of Science ®Google Scholar
• Eichenfield DZ, Sprague J, Eichenfield LF. Management of acne vulgaris: a review. JAMA. 2021;326(20):2055–2067.
   PubMed Web of Science ®Google Scholar
• Alexis AF, Woolery-Lloyd H, Williams K, et al. Racial/ethnic variations in acne: implications for treatment and skin care recommendations for acne patients with skin of color. J Drugs Dermatol. 2021;20(7):716–725.
   PubMed Web of Science ®Google Scholar
• Yentzer BA, Hick J, Reese EL, et al. Acne vulgaris in the United States: a descriptive epidemiology. Cutis. 2010;86(2):94–99.
   PubMed Web of Science ®Google Scholar
• Skroza N, Tolino E, Mambrin A, et al. Adult acne versus adolescent acne: a retrospective study of 1,167 patients. J Clin Aesthet Dermatol. 2018;11(1):21–25.
   PubMedGoogle Scholar
• Dreno B, Thiboutot D, Layton AM, et al. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol. 2015;29(6):1096–1106.
   PubMed Web of Science ®Google Scholar
• Zeichner JA, Baldwin HE, Cook-Bolden FE, et al. Emerging issues in adult female acne. J Clin Aesthet Dermatol. 2017;10(1):37–46.
   PubMedGoogle Scholar